SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical
Indications -- Psoriasis/Chronic Inflammation
An SI Board Since February 2001
Posts SubjectMarks Bans
631 42 0
Emcee:  scaram(o)uche Type:  Moderated
Introduction Compact
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
ReplyMessage PreviewFromRecsPosted
631Oxidized phospholipids are proinflammatory and proatherogenic in hypercholesteronigel bates16/7/2018
630Unpleasant side effect surprise for brodalumab: LONDON, May 26 (Reuters) - Astrnigel bates-5/26/2015
629best fit I can find..... Neuroimmunomodulation. 2013 Sep 24;21(1):1-7. [Epub ascaram(o)uche-10/3/2013
628Seen this? nature.comscaram(o)uche-9/6/2013
627About half a billion - but they're only worth a third of a Swedish Krone eacnigel bates-9/6/2013
626Must be a gatrillion shares outstanding?..... uk.finance.yahoo.com Novalon-derscaram(o)uche-9/6/2013
625STOCKHOLM, 5 September 2013 – The collaboration between Karo Bio AB and Pfizer Inigel bates-9/6/2013
624J Immunol. 2013 Aug 28. [Epub ahead of print] Cutting Edge: DNA Sensing via thescaram(o)uche-8/30/2013
623Niiiiiiiiiiiiiiiiice! Need to watch the various jak inhibitors. This was interscaram(o)uche-8/20/2013
622Basel, July 8, 2013 - Novartis announced today top-line results from the head-tonigel bates-8/20/2013
621Drug Saf. 2013 Feb;36(2):135-44. doi: 10.1007/s40264-012-0013-7. Transplantatioscaram(o)uche-8/4/2013
620Dominant suppression of inflammation by glycan-hydrolyzed IgG pnas.org Kutty Selnigel bates-6/19/2013
619PDE4 inhibition... Celgene International Sàrl, a subsidiary of Celgene Cornigel bates-6/14/2013
618Nature. 2013 Jun 2. doi: 10.1038/nature12199. [Epub ahead of print] BACH2 represcaram(o)uche-6/6/2013
617"Genomic responses in mouse models poorly mimic human inflammatory diseasestuck-2/13/2013
616ALLSCHWIL/BASEL, SWITZERLAND - 18 December 2012 - Actelion (SIX: ATLN) announcednigel bates-12/18/2012
615NDIANAPOLIS, Dec. 13, 2012 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) annnigel bates-12/14/2012
614Free Radic Biol Med. 2012 Nov 1;54C:1-16. doi: 10.1016/j.freeradbiomed.2012.10.5scaram(o)uche-12/4/2012
613PLoS One. 2012;7(11):e49547. doi: 10.1371/journal.pone.0049547. Epub 2012 Nov 14scaram(o)uche-11/21/2012
612PLoS One. 2012;7(9):e44547. Epub 2012 Sep 6. SU5416, a VEGF Receptor Inhibitorscaram(o)uche-10/13/2012
611re. IL-17... secukinumab (AIN457, Novartis) is going to phase III for psoriascaram(o)uche-10/5/2012
610Cellceutix Informed by FDA That 505(b)(2) Application Would Be an Acceptable ApSavant-6/14/2012
609One of biotech's first therapeutic projects, the magic CD4 epitope that tolescaram(o)uche-8/20/2011
608>>The evolution of drug resistance and the curious orthodoxy of aggressivetuck-6/28/2011
607ABBOTT PARK, Ill. and DREIEICH, Germany, June 21, 2011 /PRNewswire/ -- Abbott annigel bates-6/21/2011
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News